Cell-based anti-ageing drug assessment platform
Population ageing together with age-related diseases make ageing research increasingly important. Previously, the project team developed the CellAge epigenetic clock, which is based on DNA methylation and can accurately detect subtle ageing changes in human primary cells in vitro after a short-term anti-ageing drug treatment using rapamycin and trametinib. The EU-funded AgePhagy project is now connecting the CellAge clock to their autophagy drug library to test the commercial viability of this anti-ageing drug assessment platform. To further validate the clock as a robust human ageing biomarker, the team will combine its outputs with in vivo longevity assays in Drosophila. The final outcome will be an innovative accelerated discovery platform for anti-ageing drugs.
Fields of science
Funding SchemeERC-POC - Proof of Concept Grant
WC1E 6BT London
See on map